$1.23 Billion is the total value of Cormorant Asset Management, LP's 70 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXNX | New | AXONICS MODULATION TECH INC | $19,429,000 | – | 1,285,828 | +100.0% | 1.58% | – |
| SAGE | New | SAGE THERAPEUTICS INCput | $17,626,000 | – | 184,000 | +100.0% | 1.43% | – |
| TWST | New | TWIST BIOSCIENCE CORP | $16,303,000 | – | 706,064 | +100.0% | 1.32% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $9,822,000 | – | 90,000 | +100.0% | 0.80% | – |
| RARX | New | RA PHARMACEUTICALS INC | $8,026,000 | – | 441,000 | +100.0% | 0.65% | – |
| ALLK | New | ALLAKOS INC | $7,841,000 | – | 150,000 | +100.0% | 0.64% | – |
| KURA | New | KURA ONCOLOGY INC | $7,722,000 | – | 550,000 | +100.0% | 0.63% | – |
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $5,899,000 | – | 375,000 | +100.0% | 0.48% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $4,480,000 | – | 296,712 | +100.0% | 0.36% | – |
| ASNS | New | ARSANIS INC | $4,319,000 | – | 1,861,702 | +100.0% | 0.35% | – |
| PHAS | New | PHASEBIO PHARMACEUTICALS INC | $3,393,000 | – | 1,097,926 | +100.0% | 0.28% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $2,857,000 | – | 100,000 | +100.0% | 0.23% | – |
| OTLKW | New | OUTLOOK THERAPEUTICS INC*w exp 02/18/201 | $64,000 | – | 416,666 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-09-25 |
| 4 | 2024-09-24 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.